These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31444238)

  • 41. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
    Aljohani AI; Toss MS; Kurozumi S; Joseph C; Aleskandarany MA; Miligy IM; Ansari RE; Mongan NP; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jan; 179(1):79-90. PubMed ID: 31599393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.
    Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
    Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
    Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
    Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
    Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
    Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
    Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.
    Strell C; Paulsson J; Jin SB; Tobin NP; Mezheyeuski A; Roswall P; Mutgan C; Mitsios N; Johansson H; Wickberg SM; Svedlund J; Nilsson M; Hall P; Mulder J; Radisky DC; Pietras K; Bergh J; Lendahl U; Wärnberg F; Östman A
    J Natl Cancer Inst; 2019 Sep; 111(9):983-995. PubMed ID: 30816935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 55. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
    Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
    Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
    Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.
    Cedolini C; Bertozzi S; Londero AP; Seriau L; Andretta M; Agakiza D; Fongione S; Uzzau A; Risaliti A
    Int J Clin Exp Pathol; 2015; 8(10):13304-13. PubMed ID: 26722534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
    Umekita Y; Yoshida H
    Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.